CompletedPhase 1ACTRN12605000522617
A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone
Sponsor
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd
Enrollment
14 participants
Start Date
Aug 8, 2002
Study Type
Interventional
Conditions
Eligibility
Sex: FemalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This is an early-phase study looking at: A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone. It may be open to women aged 18 and older. Key requirements include: Healthy post-menopausal women Participation typically involves medical assessments and follow-up visits as part of the research.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.
Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000522617